Day: April 5, 2022

NEW YORK, April 05, 2022 (GLOBE NEWSWIRE) — Apollo Global Management, Inc. (NYSE: APO) (together with its consolidated subsidiaries, “Apollo”) plans to release financial results for the first quarter 2022 on Thursday, May 5, 2022, before the opening of trading on the New York Stock Exchange. Management will review Apollo’s financial results at 8:30 am ET via audio webcast, which will be accessible at https://www.apollo.com/stockholders/events-and-presentations. For those unable to listen to the live broadcast, there will be a replay of the webcast available at the same link one hour after the event. Apollo distributes its earnings releases via its website and email distribution lists. Those interested in receiving firm updates by email can sign up for them here. About ApolloApollo is a global, high-growth alternative asset manager....

XMT-1660 demonstrates robust activity in preclinical models of breast cancer XMT-2056 demonstrates robust activity as monotherapy, in combination with standard of care therapies and in both HER2-high and HER2-low expressing preclinical models Both programs on track to initiate Phase 1 clinical trials in mid-2022 CAMBRIDGE, Mass., April 05, 2022 (GLOBE NEWSWIRE) — Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will present three posters highlighting data for XMT-1660, XMT-2056, and the Immunosynthen ADC platform at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2022 to be held in New Orleans, Louisiana...

LONDON, April 05, 2022 (GLOBE NEWSWIRE) — Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that management will be taking part in the following conferences in April.Accelerating Bio-Innovation 2022 in Cambridge, UK on Tuesday, April 5, 2022 at 2:25pm UK. Iraj Ali, CEO, will participate in a panel entitled, “Next-Gen Immuno Oncology.” 21st Annual Needham Virtual Healthcare Conference on Tuesday, April 12, 2022 at 8:00am ET / 1:00pm UK. Iraj Ali, CEO, will give a corporate presentation. 14th Kempen Life Sciences Conference in Amsterdam, Netherlands on Wednesday, April 20, 2022. Iraj Ali, CEO, and Robert Coutts, CFO, will participate in one-on-one and small group investor meetings. Chardan’s 6th Annual Virtual Genetic...

MINNEAPOLIS, April 05, 2022 (GLOBE NEWSWIRE) — Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today announced that it will release financial results for the first quarter 2022 after the close of trading on Tuesday, May 3. Inspire’s management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments.Tuesday, May 3rd @ 5:00 p.m. Eastern Time:Domestic:  (800) 344-0786International:  (209) 905-5969Conference ID: 5029338Webcast: https://edge.media-server.com/mmc/p/inp4vfpuAbout Inspire Medical SystemsInspire is a medical technology company focused on the...

–Seasoned physician, scientist and life science executive brings expertise in clinical research and development across product life cycle– –Key appointment as Humacyte advances HAV through multiple late-stage clinical trials in initial vascular applications– DURHAM, N.C., April 05, 2022 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced the appointment of Shamik J. Parikh, M.D., as Chief Medical Officer. In this role, Dr. Parikh will lead the company’s global clinical development strategy, including oversight of the preclinical and clinical development, clinical operations, and medical affairs functions. “We are pleased to welcome Shamik to Humacyte’s leadership...

CAMBRIDGE, Mass., April 05, 2022 (GLOBE NEWSWIRE) — Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for patients with cancer, today announced that its management team will participate in the following virtual conferences in April.Needham Healthcare Conference 2022Company Presentation by Chief Financial Officer Jeff Trigilio, Wednesday, April 13, 2022, 8:00 a.m. EDTCanaccord Genuity Horizons in Oncology Virtual ConferenceFireside Chat with Chief Executive Officer Nadim Ahmed, Thursday, April 14, 2022, 2:00 p.m. EDTLive webcasts of the Needham conference presentation and Canaccord Genuity conference fireside chat will be available via the Events section of the Company’s investor relations website at https://investors.cullinanoncology.com/news-events/events. Management...

LAS VEGAS, April 05, 2022 (GLOBE NEWSWIRE) — Live Ventures Incorporated (Nasdaq: LIVE), a diversified holding company, today announced that it repurchased 65,668 shares of common stock at an average price of $31.72 per share during its fiscal 2022 second quarter ended March 31, 2022. “We believe that our strategic focus on acquiring businesses that maximize stockholder value also gives us the ability and opportunity to look inwardly at our own Company to increase that value further,” commented Jon Isaac, President and CEO of Live Ventures. “Management firmly believes our stock repurchases represent long-term value for our stockholders.” On February 20, 2018, the Company announced a $10.0 million common stock repurchase plan. The Company has repurchased 484,138 shares of its common stock for approximately $5.4 million, representing...